DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
- DOI
- 10.1007/s15010-022-01904-w
- Published
- 2023 Jun
- Container
- Infection
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s15010-022-01904-w,
title = {DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.},
author = {Madurka I and Vishnevsky A and Soriano JB and Gans SJ and Ore DJS and Rendon A and Ulrik CS and Bhatnagar S and Krishnamurthy S and Mc Harry K and Welte T and Fernandez AA and Mehes B and Meiser K and Gatlik E and Sommer U and Junge G and Rezende E and Study group},
year = {2023},
journal = {Infection},
doi = {10.1007/s15010-022-01904-w},
url = {https://doi.org/10.1007/s15010-022-01904-w}
}RIS
TY - JOUR TI - DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function. AU - Madurka I AU - Vishnevsky A AU - Soriano JB AU - Gans SJ AU - Ore DJS AU - Rendon A AU - Ulrik CS AU - Bhatnagar S AU - Krishnamurthy S AU - Mc Harry K AU - Welte T AU - Fernandez AA AU - Mehes B AU - Meiser K AU - Gatlik E AU - Sommer U AU - Junge G AU - Rezende E AU - Study group PY - 2023 JO - Infection DO - 10.1007/s15010-022-01904-w UR - https://doi.org/10.1007/s15010-022-01904-w ER -
APA
I, M., A, V., JB, S., SJ, G., DJS, O., A, R., CS, U., S, B., S, K., K, M. H., T, W., AA, F., B, M., K, M., E, G., U, S., G, J., E, R., & group, S. (2023). DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.. Infection. https://doi.org/10.1007/s15010-022-01904-w
Source records
- pubmed · retrieved 2026-09-27T14:34:13.571Z
- europe-pmc · retrieved 2026-09-27T14:34:14.809Z